The estimated Net Worth of Associates Gp Llcqvt Financ... is at least $48 Milión dollars as of 17 June 2019. Associates Financ owns over 18,204 units of Axovant Gene Therapies stock worth over $48,006,027 and over the last 6 years Associates sold AXGT stock worth over $0.
Sign up
Associates Financ AXGT stock SEC Form 4 insiders trading
Associates has made over 10 trades of the Axovant Gene Therapies stock since 2019, according to the Form 4 filled with the SEC. Most recently Associates bought 18,204 units of AXGT stock worth $151,457 on 17 June 2019.
The largest trade Associates's ever made was buying 6,666,667 units of Axovant Gene Therapies stock on 18 March 2019 worth over $10,000,001. On average, Associates trades about 1,124,140 units every 8 days since 2019. As of 17 June 2019 Associates still owns at least 22,860,013 units of Axovant Gene Therapies stock.
You can see the complete history of Associates Financ stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Axovant Gene Therapies
Over the last 6 years, insiders at Axovant Gene Therapies have traded over $0 worth of Axovant Gene Therapies stock and bought 5,401,703 units worth $20,204,515 . The most active insiders traders include Sciences Ltd. Roivant, Andrew Lo a Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of $1,890,596. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth $27,300.
What does Axovant Gene Therapies do?
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
What does Axovant Gene Therapies's logo look like?
Complete history of Associates Financ stock trades at Urovant Sciences Ltd a Axovant Gene Therapies
Axovant Gene Therapies executives and stock owners
Axovant Gene Therapies executives and other stock owners filed with the SEC include:
-
Pavan Cheruvu,
Chief Executive Officer, Director -
David Nassif,
Principal Financial and Accounting Officer and General Counsel, Chief Financial Officer -
Gavin Corcoran,
Chief Research and Development Officer -
Atul Pande,
Lead Independent Director -
Frank Torti,
Chairman of the Board -
Berndt Modig,
Independent Director -
Senthil Sundaram,
Independent Director -
Kristiina Vuori,
Director -
Eric Venker,
Director -
Parag Meswani,
Chief Commercial Officer -
Sciences Ltd. Roivant,
10% owner -
Investments (Uk) Ltd Soft B...,
-
George Bickerstaff,
Director -
Myrtle S Potter,
Director -
Roger Jeffs,
Director -
Associates Gp Llcqvt Financ...,
-
Mathew C. Bazley,
General Counsel -
Andrew Lo,